CAS 1924207-18-0

Formule : C23H23FN6O4

InChI : InChI=1S/C21H19FN6O2.C2H4O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12;1-2(3)4/h4-7,9,11H,10H2,1-3H3,(H2,24,25);1H3,(H,3,4)/t11-;/m1./s1

Code InChI : BLNAIBLTPYGILH-RFVHGSKJSA-N

SMILES : C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C.CC(=O)O

(16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetraazatetracyclo[16.3.1.0^{2,6}.0^{10,15}]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile, acetic acid

CAS : 1924207-18-0

(16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetraazatetracyclo[16.3.1.0^{2,6}.0^{10,15}]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile, acetic acid

Formule : C₂₃H₂₃FN₆O₄

Degré de pureté : 95%

Masse moléculaire : 466.466044

Ref: 54-PC1051695

Lorlatinib acetate

Produit contrôlé

CAS : 1924207-18-0

Lorlatinib acetate is a small-molecule tyrosine kinase inhibitor, which is a synthetic pharmaceutical compound designed to specifically inhibit the activity of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1). This compound is derived through complex chemical synthesis to ensure specificity and potency in its mechanism of action. Lorlatinib acetate functions by selectively binding to the ATP-binding site of ALK and ROS1, leading to the inhibition of downstream signaling pathways that promote tumor cell proliferation and survival. This targeted action results in the interruption of cancer cell growth and the induction of apoptosis in cancer cells harboring ALK and ROS1 aberrations.

Formule : C₂₃H₂₃FN₆O₄

Degré de pureté : Min. 95%

Masse moléculaire : 466.5 g/mol

Ref: 3D-ZBD20718

PF-06463922 acetate

CAS : 1924207-18-0

PF-06463922 acetate: ALK/ROS1 inhibitor, brain- penetrable, active vs crizotinib-resistant mutants, in NSCLC trials.

Formule : C₂₃H₂₃FN₆O₄

Couleur et forme : Solid

Masse moléculaire : 466.46

Ref: TM-T70060